AUS
NZ
UK
CA
USA
IND
Zelira Therapeutics Limited (ASX:ZLD), an Australian therapeutics company listed on the ASX, has sought quotation for 1,250,000 new fully paid ordinary shares after converting convertible notes from its ZLDAM security class. The conversion took place on 28 June 2026, with shares issued on 1 July 2026 at USD 0.40 each. This transaction increases Zelira’s total quoted ordinary shares to 13,147,155 and highlights ongoing activity in the company’s convertible note program. Investors monitoring dilution and capital structure should note that 2,830,270 convertible notes remain outstanding in the ZLDAM class, indicating potential for further conversions.
Key Points
- Company: Zelira Therapeutics Limited (ASX:ZLD)
- Applied for quotation of 1,250,000 fully paid ordinary shares following conversion of ZLDAM convertible notes
- Conversion date: 28 June 2026; shares issued on 1 July 2026 at USD 0.40 per share
- Total quoted ordinary shares after issuance: 13,147,155
- Outstanding securities include 2,830,270 unquoted ZLDAM convertible notes and 1,245,000 unquoted options with varying expiry dates and exercise prices
- Investors should monitor further convertible note conversions and company updates on capital management
Zelira Therapeutics Converts ZLDAM Convertible Notes into Shares on 28 June 2026
Zelira Therapeutics Limited has officially applied to the ASX for quotation of 1,250,000 new fully paid ordinary shares resulting from the conversion of securities under the ZLDAM convertible note class. The company’s update lodged on 1 July 2026 confirms the conversion occurred on 28 June 2026, with both the initial and final conversion dates being the same, indicating a single conversion event rather than multiple stages.
The newly issued shares rank equally in all respects from their issue date alongside existing ordinary shares quoted under the ZLD code on the ASX, granting holders identical rights and entitlements without restrictions or ranking differences as per the company’s disclosure.
USD 0.40 Conversion Price Highlights Foreign Currency Denomination
The conversion price was set at USD 0.40 per share, with payment made in US dollars rather than Australian dollars. This detail is significant for investors analyzing Zelira’s capital structure, as it reveals that the ZLDAM convertible notes were denominated in USD, introducing foreign exchange considerations into the company’s financing arrangements.
At USD 0.40 per share for 1,250,000 shares, this tranche’s gross value amounts to USD 500,000. However, the company has not disclosed the total face value of the ZLDAM convertible note program, original issuance terms, applicable interest rate, or overall timeline for the program’s conclusion. Investors seeking comprehensive details should consult Zelira’s previous disclosures.
Total Ordinary Shares Increase to 13,147,155 Post-Quotation
Following the quotation of these shares, Zelira’s total issued and quoted ordinary share capital stands at 13,147,155 fully paid shares, as reported in Part 4 of the Appendix 2A filing. This figure reflects the company’s capital structure after processing this conversion event with the ASX. The filing notes that these automatically generated figures may not represent the current issued capital if other ASX forms are being processed simultaneously.
The addition of 1,250,000 shares represents an increase from an estimated pre-conversion share count of approximately 11,897,155 shares, assuming no other concurrent movements. This increase is relevant for shareholders assessing dilution risks, especially given the remaining unquoted securities that could lead to further share issuances.
Outstanding 2,830,270 ZLDAM Convertible Notes Remain
Despite this conversion, 2,830,270 ZLDAM convertible notes remain outstanding and unquoted, as confirmed in the Appendix 2A filing. This sizeable amount is important for investors monitoring potential dilution, as these notes may convert into ordinary ZLD shares under the program’s terms.
The company did not disclose conversion ratios, expiry dates, or remaining terms for these notes in this update. Investors interested in the full dilution potential should review the original ZLDAM note terms in prior Zelira communications. The timing and pace of future conversions will be critical for shareholders tracking changes in Zelira’s share count.
1,245,000 Unquoted Options Also Present in Capital Structure
In addition to convertible notes, Zelira’s capital structure includes 1,245,000 unquoted options classified under ZLDAA, with various expiry dates and exercise prices. These options represent additional potential dilution if exercised before expiry.
The company did not specify exercise prices or expiry dates for these options in this update. Combined with the outstanding convertible notes, these instruments constitute a significant pool of securities that could convert or be exercised into ordinary shares, potentially impacting Zelira’s share count substantially. Investors concerned with dilution and capital efficiency should monitor future disclosures closely.
Appendix 2A Filing Process for Convertible Note Conversions
ASX-listed companies must lodge an Appendix 2A to apply for quotation of new securities resulting from conversions such as notes or options before trading can commence. This administrative process does not represent a capital raise, strategic announcement, or change in company direction. Zelira’s lodgement on 1 July 2026 complies with this requirement following the 28 June 2026 conversion.
The filing also confirms these securities are not issued under an employee incentive scheme and are directly received by the note holder, indicating an arm’s-length transaction with an external party rather than an internal equity incentive. The company did not disclose the identity of the converting note holder in this update.
Implications of the Convertible Note Conversion on Zelira’s Financing
Converting USD-denominated convertible notes into ordinary shares is a common strategy for smaller listed companies to manage debt without immediate cash repayment. This conversion reduces liabilities by exchanging debt for equity. Whether this benefits existing shareholders depends on note terms, conversion price relative to market price, and dilution levels.
Zelira did not provide commentary on the strategic rationale, whether the conversion was company or note holder initiated, or any guidance on cash position, financing needs, or timelines for converting remaining notes. Investors seeking further clarity may need to await future operational or financial updates.
Share Price Impact and Investor Outlook
The immediate impact on Zelira’s share price was not evident from public information. While such conversions are routine for small-cap ASX companies, investor reactions vary based on conversion price versus market price, dilution concerns, and sentiment toward company progress.
Key considerations for investors include the pace of further ZLDAM conversions, treatment of 1,245,000 ZLDAA options, and Zelira’s operational developments. Operating in the therapeutics sector, investors may anticipate updates that contextualize capital management activities. Upcoming milestones likely include additional conversion notices or management updates on financial and operational status.
Summary of Zelira Therapeutics’ Capital Structure After July 2026 Issuance
Post-quotation of 1,250,000 shares, Zelira’s capital structure per the Appendix 2A filing comprises 13,147,155 quoted fully paid ordinary shares (ZLD), 1,245,000 unquoted options (ZLDAA) with varying expiry and exercise terms, and 2,830,270 unquoted convertible notes (ZLDAM). These figures are automatically generated upon lodgement and may be subject to change pending other ASX processing.
The current ordinary share count of approximately 13.1 million reflects Zelira’s scale as a listed entity. However, full conversion or exercise of outstanding notes and options could materially increase the diluted share count. The company has not disclosed the maximum potential diluted share count or a timeline for these conversions or exercises.
